Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SUCLA2 antisense RNA 1 (SUCLA2-AS1)
- Target
- SUCLA2-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-protein coding RNA
01
Overview
SUCLA2 antisense RNA 1 (SUCLA2-AS1) is a long non-coding RNA transcribed from the antisense strand of the SUCLA2 locus on human chromosome 13 (location: chr13:48001389-48002620, hg38). It does not code for a protein, and its molecular function and disease relevance remain poorly characterized in the literature. As an antisense lncRNA, it may participate in regulation of gene expression or epigenetic modification processes typical of this RNA class, but there is currently no direct evidence supporting a biological or therapeutic function for SUCLA2-AS1. No information is available to support SUCLA2-AS1 as a direct therapeutic target or disease biomarker, and it should not be confused with SUCLA2, which is a distinct protein-coding gene with established metabolic and disease relevance.
- Other names
- SUCLA2 antisense RNA 1 (non-protein coding)SUCLA2-AS1ENSG00000227848 (Ensembl)NCBI Gene ID 101929410
02
Mechanism of action
None. There is no established mechanism of action for any drug targeting SUCLA2-AS1.
03
Biological functions
Currently, there are no specific functional studies demonstrating the role of SUCLA2-AS1 in cellular processes. As an antisense lncRNA, it may be involved in gene expression regulation, chromatin remodeling, or RNA-RNA interactions, but functional evidence is lacking in the literature and databases
04
Disease associations
No direct disease association has been described for SUCLA2-AS1. There are no established links between SUCLA2-AS1 expression and cancer, inflammation, neurodegeneration, or other diseases as of current knowledge
05
Safety considerations
None reported. There are no known therapeutic concerns or safety risks tied specifically to SUCLA2-AS1.
Beyond the preview
Go deeper on SUCLA2 antisense RNA 1 (SUCLA2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SUCLA2 antisense RNA 1 (SUCLA2-AS1).